Related content

Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent

By Session D. R.   Kalli K. R.   Tummon I. S.   Damario M. A.   Dumesic D. A.  

Gynecological Endocrinology, Vol. 17, Iss. 5, 2003-10 ,pp. : 405-407

Informa Healthcare

Access to resources Recommend Favorite

The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study

By Pashov Alexandr I.   Tskhay Vitaly B.   Ionouchene Svetlana V.  

Gynecological Endocrinology, Vol. 28, Iss. 7, 2012-07 ,pp. : 559-561

Informa Healthcare

Access to resources Recommend Favorite

Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option

By Gadducci Angiolo   Sergiampietri Claudia   Guiggi Ilaria  

Gynecological Endocrinology, Vol. 29, Iss. 9, 2013-09 ,pp. : 811-816

Informa Healthcare

Access to resources Recommend Favorite

Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women

By Morelli Michele   Di Cello Annalisa   Venturella Roberta   Mocciaro Rita   D’Alessandro Pietro   Zullo Fulvio  

Gynecological Endocrinology, Vol. 29, Iss. 2, 2013-02 ,pp. : 156-159

Informa Healthcare

Access to resources Recommend Favorite

Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer

By Yamazawa Koji   Hirai Makiko   Fujito Atsuya   Nishi Hirokata   Terauchi Fumitoshi   Ishikura Hiroshi   Shozu Makio   Isaka Keiichi  

Human Reproduction, Vol. 22, Iss. 7, 2007-07 ,pp. : 1953-1958

Oxford University Press

Access to resources Recommend Favorite